PURPOSE: Codeine is an analgesic drug acting on μ-opioid receptors predominantly via its metabolite morphine formed almost exclusively by CYP2D6. Genetic polymorphisms in CYP2D6 are associated with diminished pain relief and/or severe opioid side effects. In Chinese individuals, CYP2D6*10 is the most common allele with reduced enzyme activity. In this study, we investigated the effect of this allele on the pharmacokinetics of codeine and its metabolites. METHOD: A blood sample was collected from healthy Mongolian volunteers for CYP2D6 genotyping using a PCR-RFLP assay. A pharmacokinetic study was then carried out in three groups with CYP2D6*1/*1 (n=10), CYP2D6*1/*10 (n=10) and CYP2D6*10/*10 (n=9) genotypes by collecting serial blood samples for determination of plasma levels of codeine and its metabolites, morphine, morphine 3-glucuronide (M3G) and morphine 6-glucuronide (M6G) before and after a single 30-mg oral dose of codeine phosphate. Codeine and its metabolites were measured by LC-MS/MS. RESULTS: No significant differences were observed in the pharmacokinetic parameters of codeine in the three genotype groups. However, the C( max) and AUC(0-∞) of morphine, M3G and M6G were significantly different between the study groups (P<0.05). Compared with the *1/*1 group, the AUC(0-∞) for morphine in the *1/*10 and *10/*10 groups decreased by ratios (95 % CI) of 0.93 (0.26-1.59) and 0.494 (0.135-0.853) respectively. Corresponding ratios for M3G were 0.791 (0.294-1.288) and 0.615 (0.412-0.818) and for M6G were 0.643 (0.39-0.957) and 0.423 (0.267-0.579). CONCLUSION: This study demonstrates that the CYP2D6*10 allele plays an important role in the pharmacokinetics of the O-demethylated metabolites of codeine after oral administration.
PURPOSE:Codeine is an analgesic drug acting on μ-opioid receptors predominantly via its metabolite morphine formed almost exclusively by CYP2D6. Genetic polymorphisms in CYP2D6 are associated with diminished pain relief and/or severe opioid side effects. In Chinese individuals, CYP2D6*10 is the most common allele with reduced enzyme activity. In this study, we investigated the effect of this allele on the pharmacokinetics of codeine and its metabolites. METHOD: A blood sample was collected from healthy Mongolian volunteers for CYP2D6 genotyping using a PCR-RFLP assay. A pharmacokinetic study was then carried out in three groups with CYP2D6*1/*1 (n=10), CYP2D6*1/*10 (n=10) and CYP2D6*10/*10 (n=9) genotypes by collecting serial blood samples for determination of plasma levels of codeine and its metabolites, morphine, morphine 3-glucuronide (M3G) and morphine 6-glucuronide (M6G) before and after a single 30-mg oral dose of codeine phosphate. Codeine and its metabolites were measured by LC-MS/MS. RESULTS: No significant differences were observed in the pharmacokinetic parameters of codeine in the three genotype groups. However, the C( max) and AUC(0-∞) of morphine, M3G and M6G were significantly different between the study groups (P<0.05). Compared with the *1/*1 group, the AUC(0-∞) for morphine in the *1/*10 and *10/*10 groups decreased by ratios (95 % CI) of 0.93 (0.26-1.59) and 0.494 (0.135-0.853) respectively. Corresponding ratios for M3G were 0.791 (0.294-1.288) and 0.615 (0.412-0.818) and for M6G were 0.643 (0.39-0.957) and 0.423 (0.267-0.579). CONCLUSION: This study demonstrates that the CYP2D6*10 allele plays an important role in the pharmacokinetics of the O-demethylated metabolites of codeine after oral administration.
Authors: Margaret T Susce; Elaina Murray-Carmichael; Jose de Leon Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2006-04-24 Impact factor: 5.067
Authors: J Kirchheiner; H Schmidt; M Tzvetkov; J-T H A Keulen; J Lötsch; I Roots; J Brockmöller Journal: Pharmacogenomics J Date: 2006-07-04 Impact factor: 3.550
Authors: Yvan Gasche; Youssef Daali; Marc Fathi; Alberto Chiappe; Silvia Cottini; Pierre Dayer; Jules Desmeules Journal: N Engl J Med Date: 2004-12-30 Impact factor: 91.245
Authors: Hongwu Shen; Minxia M He; Houfu Liu; Steven A Wrighton; Li Wang; Bin Guo; Chuan Li Journal: Drug Metab Dispos Date: 2007-04-30 Impact factor: 3.922
Authors: K Persson; S Sjöström; I Sigurdardottir; V Molnár; M Hammarlund-Udenaes; A Rane Journal: Br J Clin Pharmacol Date: 1995-02 Impact factor: 4.335
Authors: Jan Grzegorzewski; Janosch Brandhorst; Kathleen Green; Dimitra Eleftheriadou; Yannick Duport; Florian Barthorscht; Adrian Köller; Danny Yu Jia Ke; Sara De Angelis; Matthias König Journal: Nucleic Acids Res Date: 2021-01-08 Impact factor: 16.971
Authors: Dmitrij A Sychev; Ghulam Md Ashraf; Andrey A Svistunov; Maksim L Maksimov; Vadim V Tarasov; Vladimir N Chubarev; Vitalij A Otdelenov; Natal'ja P Denisenko; George E Barreto; Gjumrakch Aliev Journal: Drug Des Devel Ther Date: 2018-05-08 Impact factor: 4.162
Authors: Mark A Davison; Daniel T Lilly; Shyam A Desai; Victoria D Vuong; Jessica Moreno; Carlos Bagley; Owoicho Adogwa Journal: Global Spine J Date: 2019-05-16